The Korean journal of helicobacter and upper gastrointestinal research (대한상부위장관⦁헬리코박터학회지)

Korean College of Helicobacter and upper Gastrointestinal Reseaarch (대한상부위장관ㆍ헬리코박터학회)
권호 표지
DOI QR코드

DOI QR Code

Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor

전이성 위장관 기질종양의 수술 후 완치

  • Park, Eun Hyea (Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Jin Il (Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Cheung, Dae Yong (Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Soo-Heon (Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 박은혜 (가톨릭대학교 의과대학 여의도성모병원 소화기내과) ;
  • 김진일 (가톨릭대학교 의과대학 여의도성모병원 소화기내과) ;
  • 정대영 (가톨릭대학교 의과대학 여의도성모병원 소화기내과) ;
  • 박수헌 (가톨릭대학교 의과대학 여의도성모병원 소화기내과)
  • Received : 2018.05.03
  • Accepted : 2018.06.08
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib mesylate. GISTs are resistant to conventional chemotherapy, and radiation therapy is not significantly beneficial for GISTs. With the development of imatinib mesylate, approximately 81.6% of patients with advanced and metastatic GIST exhibit an effect above the stabilization response, thereby increasing the survival time. However, imatinib mesylate alone is unlikely to cure metastatic GISTs. Even with a partial or stable response, imatinib mesylate may be used for a longer time period. However, resection of grossly visible lesions should be considered for patients with a stable response during surgical treatment. In this study, we present a case of GIST with liver metastasis after imatinib mesylate treatment, which was followed up without recurrence after partial resection.

Keywords

References

  1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-1220. https://doi.org/10.1016/S0046-8177(99)90040-0
  2. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
  3. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58. https://doi.org/10.1097/00000658-200001000-00008
  4. Molinas Mandel N, Selcukbiricik F, Kanitez M, et al. Clinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors. J BUON 2016;21:360-365.
  5. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480. https://doi.org/10.1056/NEJMoa020461
  6. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-2331. https://doi.org/10.1200/JCO.2005.05.3439
  7. Miettinen M, Lasota J. Gastrointestinal stromal tumors-- definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12. https://doi.org/10.1007/s004280000338
  8. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. https://doi.org/10.1097/01.pas.0000146010.92933.de
  9. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-5058. https://doi.org/10.1038/sj.onc.1204704
  10. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-710. https://doi.org/10.1126/science.1079666
  11. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-578. https://doi.org/10.1093/annonc/mdi127
  12. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625. https://doi.org/10.1200/JCO.2007.13.4403
  13. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.
  14. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009;35:739-745. https://doi.org/10.1016/j.ejso.2008.11.005
  15. Park SJ, Ryu MH, Ryoo BY, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol 2014;21:4211-4217. https://doi.org/10.1245/s10434-014-3866-4